Ex Parte Stankov - Page 1

                             The opinion in support of the decision being entered today                     
                                     is not binding precedent of the Board.                                 
                      UNITED STATES PATENT AND TRADEMARK OFFICE                                             
                           BEFORE THE BOARD OF PATENT APPEALS                                               
                                        AND INTERFERENCES                                                   
                                    Ex parte BOJIDAR M. STANKOV                                             
                                            Appeal 2007-3261                                                
                                          Application 09/854,802                                            
                                         Technology Center 1600                                             
                                      Decided:  September 20, 2007                                          
               Before DEMETRA J. MILLS, LORA M. GREEN, and RICHARD M.                                       
               LEBOVITZ, Administrative Patent Judges.                                                      
               LEBOVITZ, Administrative Patent Judge.                                                       
                                         DECISION ON APPEAL                                                 
                      This is a decision on appeal from the final rejection of claims 16-18                 
               and 20-24.  We have jurisdiction under 35 U.S.C.  6(b).  We affirm.                         
                                         STATEMENT OF CASE                                                  
                      Melatonin (N-acetyl-5-methoxytryptamine) is a naturally-occurring                     
               compound which is known to induce and improve the depth and quality of                       
               sleep (Spec. 2).  Because of its short half-life in the blood, exogenously                   
               administered melatonin has been found to be insufficient to regulate sleep                   
               (Spec. 2-3).  To address this problem, melatonin has been administered in                    

Page:  1  2  3  4  5  6  7  8  9  10  11  Next

Last modified: September 9, 2013